173 related articles for article (PubMed ID: 22892553)
1. Toward a more rational policy for autologous hematopoietic stem cell mobilization.
Devine SM
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1468-70. PubMed ID: 22892553
[No Abstract] [Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor (Mozobil).
Med Lett Drugs Ther; 2010 Apr; 52(1335):27-8. PubMed ID: 20360661
[No Abstract] [Full Text] [Related]
5. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
7. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
8. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
10. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation.
Mohty M; Duarte RF; Croockewit S; Hübel K; Kvalheim G; Russell N
Leukemia; 2011 Jan; 25(1):1-6. PubMed ID: 21224858
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
12. [Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
Hansen PB; Gaarsdal E
Ugeskr Laeger; 2009 Nov; 171(45):3272-5. PubMed ID: 19887056
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
Jantunen E; Varmavuo V; Valtola J
Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
15. Optimizing stem cell collection through CXCR4 antagonists.
Mahaseth H; Kaufman J
Front Biosci (Schol Ed); 2012 Jan; 4(2):611-9. PubMed ID: 22202080
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.
Grignani G; Perissinotto E; Cavalloni G; Carnevale Schianca F; Aglietta M
J Clin Oncol; 2005 Jun; 23(16):3871-2; author reply 3872-3. PubMed ID: 15923599
[No Abstract] [Full Text] [Related]
17. Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced
Lidonnici MR; Aprile A; Frittoli MC; Mandelli G; Paleari Y; Spinelli A; Gentner B; Zambelli M; Parisi C; Bellio L; Cassinerio E; Zanaboni L; Cappellini MD; Ciceri F; Marktel S; Ferrari G
Haematologica; 2017 Apr; 102(4):e120-e124. PubMed ID: 28034992
[No Abstract] [Full Text] [Related]
18. Plerixafor.
DiPersio JF; Uy GL; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2009 Feb; 8(2):105-6. PubMed ID: 19180104
[No Abstract] [Full Text] [Related]
19. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
Giralt S; Costa L; Schriber J; Dipersio J; Maziarz R; McCarty J; Shaughnessy P; Snyder E; Bensinger W; Copelan E; Hosing C; Negrin R; Petersen FB; Rondelli D; Soiffer R; Leather H; Pazzalia A; Devine S
Biol Blood Marrow Transplant; 2014 Mar; 20(3):295-308. PubMed ID: 24141007
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
Jantunen E; Varmavuo V; Juutilainen A; Kuittinen T; Mahlamäki E; Mäntymaa P; Nousiainen T
Ann Hematol; 2012 Jul; 91(7):1073-9. PubMed ID: 22302373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
